Sabby Management, LLC Caladrius Biosciences, Inc. Transaction History

Sabby Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.41 - $0.74 $11,288 - $20,375	-27,534 Reduced 1.16%	2,343,991 $1.24 Million
Q1 2022 May 16, 2022	BUY	$0.63 - $1.03 $481,702 - $787,545	764,607 Added 47.58%	2,371,525 $1.48 Million
Q4 2021 Feb 14, 2022	BUY	$0.83 - $1.22 $541,726 - $796,273	652,683 Added 68.4%	1,606,918 $1.35 Million
Q3 2021 Nov 15, 2021	BUY	$1.15 - $1.57 $1.1 Million - $1.5 Million	954,235 New	954,235 $1.16 Million
Q2 2021 Aug 16, 2021	SELL	$1.4 - $1.9 $678,958 - $921,443	-484,970 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$1.44 - $2.89 $698,356 - $1.4 Million	484,970 New	484,970 $936,000
Q4 2020 Feb 16, 2021	SELL	$1.39 - $1.87 $133,441 - $179,521	-96,001 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$1.6 - $3.0 $153,601 - $288,003	96,001 New	96,001 $173,000

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.